These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 20372086)

  • 1. Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs.
    Steelman LS; Abrams SL; Shelton JG; Chappell WH; Bäsecke J; Stivala F; Donia M; Nicoletti F; Libra M; Martelli AM; McCubrey JA
    Cell Cycle; 2010 Apr; 9(8):1629-38. PubMed ID: 20372086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy.
    Abrams SL; Steelman LS; Shelton JG; Wong EW; Chappell WH; Bäsecke J; Stivala F; Donia M; Nicoletti F; Libra M; Martelli AM; McCubrey JA
    Cell Cycle; 2010 May; 9(9):1781-91. PubMed ID: 20436278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia.
    Blalock WL; Navolanic PM; Steelman LS; Shelton JG; Moye PW; Lee JT; Franklin RA; Mirza A; McMahon M; White MK; McCubrey JA
    Leukemia; 2003 Jun; 17(6):1058-67. PubMed ID: 12764369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation.
    Shelton JG; Moye PW; Steelman LS; Blalock WL; Lee JT; Franklin RA; McMahon M; McCubrey JA
    Leukemia; 2003 Sep; 17(9):1765-82. PubMed ID: 12970777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergy between PI3K/Akt and Raf/MEK/ERK pathways in IGF-1R mediated cell cycle progression and prevention of apoptosis in hematopoietic cells.
    Shelton JG; Steelman LS; White ER; McCubrey JA
    Cell Cycle; 2004 Mar; 3(3):372-9. PubMed ID: 14726697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.
    Chappell WH; Steelman LS; Long JM; Kempf RC; Abrams SL; Franklin RA; Bäsecke J; Stivala F; Donia M; Fagone P; Malaponte G; Mazzarino MC; Nicoletti F; Libra M; Maksimovic-Ivanic D; Mijatovic S; Montalto G; Cervello M; Laidler P; Milella M; Tafuri A; Bonati A; Evangelisti C; Cocco L; Martelli AM; McCubrey JA
    Oncotarget; 2011 Mar; 2(3):135-64. PubMed ID: 21411864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ability of the activated PI3K/Akt oncoproteins to synergize with MEK1 and induce cell cycle progression and abrogate the cytokine-dependence of hematopoietic cells.
    Shelton JG; Blalock WL; White ER; Steelman LS; McCubrey JA
    Cell Cycle; 2004 Apr; 3(4):503-12. PubMed ID: 15004527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy.
    Abrams SL; Steelman LS; Shelton JG; Chappell W; Bäsecke J; Stivala F; Donia M; Nicoletti F; Libra M; Martelli AM; McCubrey JA
    Cell Cycle; 2010 May; 9(9):1839-46. PubMed ID: 20436269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.
    Steelman LS; Franklin RA; Abrams SL; Chappell W; Kempf CR; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo P; Ruvolo V; Evangelisti C; Martelli AM; McCubrey JA
    Leukemia; 2011 Jul; 25(7):1080-94. PubMed ID: 21494257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells.
    Shelton JG; Steelman LS; Lee JT; Knapp SL; Blalock WL; Moye PW; Franklin RA; Pohnert SC; Mirza AM; McMahon M; McCubrey JA
    Oncogene; 2003 Apr; 22(16):2478-92. PubMed ID: 12717425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells.
    Aksamitiene E; Kholodenko BN; Kolch W; Hoek JB; Kiyatkin A
    Cell Signal; 2010 Sep; 22(9):1369-78. PubMed ID: 20471474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
    Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
    Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells.
    Taylor JR; Lehmann BD; Chappell WH; Abrams SL; Steelman LS; McCubrey JA
    Oncotarget; 2011 Aug; 2(8):610-26. PubMed ID: 21881167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors.
    Ewald F; Nörz D; Grottke A; Hofmann BT; Nashan B; Jücker M
    Invest New Drugs; 2014 Dec; 32(6):1144-54. PubMed ID: 25152244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feedback loops blockade potentiates apoptosis induction and antitumor activity of a novel AKT inhibitor DC120 in human liver cancer.
    Yang F; Deng R; Qian XJ; Chang SH; Wu XQ; Qin J; Feng GK; Ding K; Zhu XF
    Cell Death Dis; 2014 Mar; 5(3):e1114. PubMed ID: 24625973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Chappell WH; Abrams SL; Wong EW; Chang F; Lehmann B; Terrian DM; Milella M; Tafuri A; Stivala F; Libra M; Basecke J; Evangelisti C; Martelli AM; Franklin RA
    Biochim Biophys Acta; 2007 Aug; 1773(8):1263-84. PubMed ID: 17126425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
    Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
    Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells.
    Steelman LS; Navolanic P; Chappell WH; Abrams SL; Wong EW; Martelli AM; Cocco L; Stivala F; Libra M; Nicoletti F; Drobot LB; Franklin RA; McCubrey JA
    Cell Cycle; 2011 Sep; 10(17):3003-15. PubMed ID: 21869603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential abilities of the Raf family of protein kinases to abrogate cytokine dependency and prevent apoptosis in murine hematopoietic cells by a MEK1-dependent mechanism.
    Hoyle PE; Moye PW; Steelman LS; Blalock WL; Franklin RA; Pearce M; Cherwinski H; Bosch E; McMahon M; McCubrey JA
    Leukemia; 2000 Apr; 14(4):642-56. PubMed ID: 10764150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.